Kaftrio : un médicament "miracle" pour les patients atteints de la mucoviscidose • FRANCE 24

Telethon 37th Edition: A Milestone in Rare Disease Research

Overview of the Telethon Event

• The 37th edition of the Telethon took place last weekend, raising over 80 million euros.

• This exceptional mobilization from donors supports research and highlights rare diseases, such as cystic fibrosis (mucoviscidosis).

Understanding Cystic Fibrosis

• Cystic fibrosis is a genetic disease caused by a mutation in the CFTR gene, affecting approximately 7,500 people in France.

• Symptoms include chronic respiratory issues due to thickened mucus that traps bacteria and dust, leading to repeated infections and inflammation.

Pathophysiology of Cystic Fibrosis

• The CFTR protein's malfunction results in mucus becoming thick and sticky, causing severe lung and digestive problems.

• Patients experience progressive decline in lung function; children are born with healthy lungs but lose capacity over time.

Advances in Treatment

• The life expectancy for cystic fibrosis patients has increased from around 10 years to about 50 years due to advancements like neonatal screening introduced nationwide in France since 2022.

• A new medication called "Kaftrio," approved in France since 2021, significantly improves lung function through a combination therapy targeting the underlying genetic cause rather than just symptoms.

Impact of Kaftrio on Patient Care

• Kaftrio is available for patients aged over six who have the most common CF mutation (F508del), benefiting approximately 85% of patients currently eligible for treatment.

• Patients report remarkable improvements; many who previously required extensive care now experience significant relief after starting this medication.

Future Directions: Gene Therapy Potential

• Researchers express optimism about future treatments using CRISPR technology to potentially correct the genetic mutation responsible for cystic fibrosis.

• While still early in clinical trials, gene editing holds promise for long-term solutions beyond current therapies aimed at symptom management.